Iterum Therapeutics PLC reports results for the quarter ended December 31 - Earnings Summary

Iterum Therapeutics

07/02/2025 14:32

* Iterum Therapeutics PLC  ITRM.OQ  reported a quarterly
adjusted
loss of 23 cents​​ per share for the quarter ended December 31,
higher than the same quarter last year, when the company
reported EPS of -94 cents.  The mean expectation of two analysts
for the quarter was for a loss of 21 cents per share. Wall
Street expected results to range from -26 cents to -17 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Iterum Therapeutics PLC's reported EPS for the quarter was
a
loss of 25 cents​.
    * The company reported a quarterly loss of $6.58 million.
    * Iterum Therapeutics PLC shares had fallen by 15.8% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 13.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Iterum
Therapeutics PLC is $7.50 
This summary was machine generated from LSEG data February 7 at
02:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -0.21          -0.23          Missed
 Sep. 30 2024      -0.20          -0.30          Missed
 Jun. 30 2024      -0.45          -0.30          Beat
 Mar. 31 2024      -0.72          -0.46          Beat